A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Name: A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Published: 2026
License: Public Domain

AbbVie · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, pivekimab sunirine (pvek), azacitidine, venetoclax, interventional, phase2, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Related documents